Issues
-
Cover Image
Cover Image
The molecular mechanisms that promote lung metastases are not fully understood. Wu, Li, Ji, and Liu et al. show that small extracellular vesicles (sEV) derived from head-and-neck-cancer tumor cells localize to areas with lung macrophages and modulate macrophage polarization. Interactions between sEVs and macrophages drive the macrophages to an immunosuppressive phenotype that facilitates metastatic spread to the lungs. Targeting this metastasis-promoting mechanism can enhance the therapeutic efficacy of anti–PD-1. The data indicate that in head and neck cancer, tumor cell–derived sEVs contribute to the formation of the lung premetastatic niche via interactions with lung macrophages, highlighting potential therapeutic targets. Read more in this issue on page 161. Original image from Fig. 1I. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
What We're Reading
Meeting Report
Review
Research Articles
Tumor-Derived RAB21+ABHD12+ sEVs Drive the Premetastatic Microenvironment in the Lung
RAB21+ABHD12+ sEVs derived from head and neck cancer tumor cells contribute to the formation of the immunosuppressive, premetastatic niche in the lung. Data highlight how sEVs are a potential therapeutic target for enhancing the efficacy of immunotherapy.
RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
HCC is a leading cause of cancer-related death globally and existing immunotherapy is not very effective. The authors report targeting the retinoic acid pathway through RALDH1 inhibition could be a novel immunotherapeutic approach for HCC.
M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
CD137 is a promising target for enhancing cancer immunotherapy. The authors show that the CD137 immune agonist M9657 induces potent mesothelin-dependent antitumor activity without the systemic immune activation seen with CD137 agonist monotherapies.
Lymph Node–Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors
TCR T-cell therapy has modest therapeutic efficacy against solid tumors. The authors show enhanced ability of TCR T cells to eradicate solid tumors by combination with lymph node–targeted AMP-peptide vaccination in mouse and human models.
Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH–Wild-Type High-Grade Gliomas
The immune landscape of IDH–wild-type, high-grade gliomas is revealed. Key myeloid and T-cell subsets are identified, as well as interactions that impact antitumor immunity in the tumor microenvironment. This study highlights potential therapeutic targets for treating glioma.
Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages
The authors identify a novel function for CD99 in inducing tumor cell phagocytosis and reprogramming of macrophages, thus suggesting that agonistic antibodies against CD99 may be exploited to improve immunotherapeutic strategies for EWS.
Immune Modulation of Innate and Adaptive Responses Restores Immune Surveillance and Establishes Antitumor Immunologic Memory
The virus-like-vesicle, CARG-2020, which combines oncolytic activity with immune-modulatory effects, is demonstrated to remodel the tumor microenvironment. CARG-2020 used as a therapy induces complete tumor regression, generates immune memory, and protects against future tumor recurrence.
Correction
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.